Passive Aβ Immunotherapy: Current Achievements and Future Perspectives

Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry
Stephan SchillingC A Lemere

Abstract

Passive immunotherapy has emerged as a very promising approach for the treatment of Alzheimer’s disease and other neurodegenerative disorders, which are characterized by the misfolding and deposition of amyloid peptides. On the basis of the amyloid hypothesis, the majority of antibodies in clinical development are directed against amyloid β (Aβ), the primary amyloid component in extracellular plaques. This review focuses on the current status of Aβ antibodies in clinical development, including their characteristics and challenges that came up in clinical trials with these new biological entities (NBEs). Emphasis is placed on the current view of common side effects observed with passive immunotherapy, so-called amyloid-related imaging abnormalities (ARIAs), and potential ways to overcome this issue. Among these new ideas, a special focus is placed on molecules that are directed against post-translationally modified variants of the Aβ peptide, an emerging approach for development of new antibody molecules.

References

Feb 15, 1993·Archives of Biochemistry and Biophysics·D L MillerK Iqbal
Nov 24, 1998·Journal of Neuropathology and Experimental Neurology·R HosodaT Iwatsubo
Jun 13, 2000·Nature·C RussoJ K Teller
Oct 13, 2006·Biochemistry·Stephan SchillingHans-Ulrich Demuth
Jan 2, 2009·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Daniela PuzzoOttavio Arancio
Feb 7, 2009·BMJ : British Medical Journal·Alistair Burns, Steve Iliffe
Feb 7, 2009·BMJ : British Medical Journal·Alistair Burns, Steve Iliffe
Jun 13, 2009·Biochemistry·Dagmar SchlenzigHans-Ulrich Demuth
Jan 20, 2010·Lancet Neurology·Clifford R JackJohn Q Trojanowski
Jan 29, 2010·The New England Journal of Medicine·Henry W Querfurth, Frank M LaFerla
Sep 3, 2010·Clinical Pharmacology and Therapeutics·M D CarterD F Weaver
Oct 5, 2010·Nature Reviews. Drug Discovery·Andy Extance
Apr 8, 2011·Annals of Neurology·Daniela PuzzoOttavio Arancio
May 27, 2011·Science Translational Medicine·Y Joy YuMark S Dennis
Jun 22, 2011·Proceedings of the National Academy of Sciences of the United States of America·Jin-Dong DingCatherine Bowes Rickman
Jul 26, 2011·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Reisa A SperlingRachel J Schindler
Oct 4, 2011·The Journal of Biological Chemistry·Sadim JawharThomas A Bayer
Jun 28, 2012·Journal of Alzheimer's Disease : JAD·Daniela Puzzo, Ottavio Arancio
Jul 13, 2012·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Oskar AdolfssonRyan J Watts
Jan 12, 2013·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Martin PrinceCleusa P Ferri
Feb 15, 2013·Journal of Neurochemistry·Lei Gu, Zhefeng Guo
Mar 13, 2013·Lancet Neurology·Victor L VillemagneUNKNOWN Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group
Apr 26, 2013·Biochemistry·Christina J CrumpYue-Ming Li
May 3, 2013·Science Translational Medicine·Jessica A CouchRyan J Watts
Oct 30, 2013·Journal of Alzheimer's Disease : JAD·Markus MorawskiSteffen Roßner

❮ Previous
Next ❯

Citations

Apr 14, 2019·British Journal of Pharmacology·Erika CeconRalf Jockers
Sep 4, 2019·Acta Neuropathologica Communications·Lieke JäkelMarcel M Verbeek
Jan 7, 2020·Médecine sciences : M/S·Hélène Blasco, Pierre-François Pradat
Jan 25, 2020·International Journal of Molecular Sciences·Pi-Shan SungKuen-Jer Tsai
Sep 19, 2019·Human Vaccines & Immunotherapeutics·Ping KwanLarry Baum
Apr 13, 2020·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Antero SalminenAnu Kauppinen
Aug 11, 2020·EMBO Molecular Medicine·Assunta SenatoreAdriano Aguzzi
Apr 30, 2020·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Somin KwonEliezer Masliah
Dec 15, 2020·Neurobiology of Disease·Doris Lambracht-WashingtonRoger N Rosenberg
Jan 27, 2020·Neurobiology of Disease·Senthilkumar KrishnaswamyEinar M Sigurdsson
Apr 20, 2020·Biochimica Et Biophysica Acta. Proteins and Proteomics·Vivian HookGregory Hook
Jun 30, 2021·Journal of Controlled Release : Official Journal of the Controlled Release Society·Tao SunCynthia A Lemere
Jul 10, 2021·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Katarzyna PotyrakAdam Szeląg
Sep 30, 2021·Scientific Reports·Faisal AbedinSuren A Tatulian

❮ Previous
Next ❯

Methods Mentioned

BETA
imaging techniques

Related Concepts

Related Feeds

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.

© 2022 Meta ULC. All rights reserved